Journal of Clinical Oncology
Articles in this Issue
A multi-center, single-arm, phase II study of pemigatinib combined with immune checkpoint inhibitor in FGFR1/2/3 alteration advanced solid tumor.
TPS2692 Background: FGFR mutations are a significant genetic factor contributing to the onset and progression of various cancers. FGFRs are aberrantly act...
Characterization of the immune microenvironment and spatial phenotypes across HER2 subtypes in advanced or metastatic breast cancer.
1037 Background: Breast cancer is defined by HER2 and hormone receptors (HR) status, which influence the clinical outcomes. HER2-positive has been traditi...
Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (BULLSEYE trial).
5009 Background: [ 177 Lu]Lu-PSMA-617 (Pluvicto) is a novel treatment for patients with metastatic castration resistant prostate c...
The therapeutic effect of interstitial brachytherapy on locally inoperable giant osteosarcoma masses.
e23501 Background: Osteosarcoma is insensitive to conventional radiotherapy, and conventional external radiation therapy for large tumors cannot meet the...
Real-world survival outcomes and adverse events with adjuvant osimertinib in resected EGFR mutation-positive non-small cell lung cancer.
e20003 Background: Adjuvant osimertinib (AO) significantly improved disease-free survival and overall survival among patients with resected stage IB to II...
Impact of expanding Medicaid contracts at Dana-Farber Cancer Institute.
e13513 Background: In December 2020, Dana-Farber Cancer Institute (DFCI) contracted with Boston Medical Center HealthNet Plan (BMCHP), the second largest...
Outcomes of temozolomide and capecitabine chemotherapy used in neuroendocrine and endocrine tumours: A real-world comparison of treatment evidence in Alberta, Canada, from 2011-2021.
e23064 Background: Capecitabine and temozolomide (CAPTEM) have proven effective in improving progression-free survival (PFS) in pancreatic neuroendocrine...
Risk of pre-cancerous advanced adenomas of the colon in long distance runners.
3619 Background: Exercise induced gastrointestinal injury is believed to be associated with reduced blood flow to the intestines during long distance runn...
Risk of second primary hematological malignancy post CAR-T cell therapy in relapsed/refractory multiple myeloma: Propensity-matched analysis using TriNetX database.
7523 Background: The Food and Drug Administration (FDA) issued a black box warning regarding the risk of T-cell lymphoma post CAR-T cell therapy has drawn...
A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma.
6034 Background: Currently, clinical studies have shown that patients with tumor remission after preoperative induction chemotherapy have a higher surviva...
Real world study of 171 cases of mucinous ovarian carcinoma.
e17583 Background: To provide a reference for the diagnosis and treatment of mucinous ovarian carcinoma (MOC), we retrospectively investigate its clinicop...
Efbemalenograstim alfa for primary prophylaxis of chemotherapy-induced neutropenia in patients with ovarian and cervical cancer: A single-arm, multicenter clinical trial.
e17566 Background: Neutropenia is the most common hematological toxicity of myelosuppressive chemotherapy. To observe the efficacy and safety of efbemalen...
Trial in progress: A phase 3 randomized study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma (CLEAR CSCC).
TPS9612 Background: Cemiplimab 350 mg administered intravenously every 3 weeks is approved for the treatment of advanced cutaneous squamous cell carcinoma...
Modeling the economic impact of a CIZ1B biomarker blood test for lung cancer screening in high-risk populations.
e15091 Background: Lung cancer screening using low-dose computed tomography (LDCT) is an established method for reducing lung cancer mortality in high-ris...
High grade serous ovarian cancer differentiation and invasion post chemotherapy: Role of NRF2.
e17611 Background: Epithelial ovarian cancer accounts for 90% of ovarian cancer diagnoses, about 70% of which are high grade serous ovarian cancer (HGSOC)...
Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: A phase 2 randomized clinical trial.
e18078 Background: In recent years, endoscopic surgery has become the first-line treatment for surgically resectable recurrent nasopharyngeal carcinoma (r...
Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1.
TPS2687 Background: Many patients do not respond to anti-PD(L)-1-based therapies and most responders eventually develop resistance. Thus, the development...
Optimizing disparities in time to treatment: A comprehensive multidisciplinary clinic.
e13569 Background: Gastrointestinal (GI) cancer patients need personalized treatment plans often requiring a multimodal approach that includes surgery, ra...
Career transitions and practice patterns among international medical graduates in oncology workforce: A US nationwide analysis.
9009 Background: International Medical Graduates (IMGs) are a vital component of the US oncology workforce, representing nearly half of practicing medical...
Perception of postoperative functional status in gastrointestinal and hepatobiliary cancer patients over 80.
11117 Background: Advanced age independently predicts poor surgical outcomes in cancer patients, making octogenarians a particularly high-risk surgical po...
Predictors of chemotherapy-induced cardiotoxicity among African American women with breast cancer: A retrospective study.
e24002 Background: African American women who were treated for breast cancer with anti-HER2 monoclonal antibody and/or anthracyclines experience an increa...
IPDsim: An interpretable model to assess individual clinical antagonism in combination therapies for cancers.
e13646 Background: Combination therapies, integrating chemotherapies, biologics, and radiotherapies, have shown promise in treating cancer and the potenti...
Gender disparities in major adverse cardiovascular and cerebrovascular events among gastric cancer patients: A nationwide analysis (NIS 2016–2021).
e16096 Background: Gastric cancer remains a leading cause of cancer mortality, with gender disparities in outcomes influenced by cardiovascular risk facto...
Immunological signatures and clinical outcomes in patients with thymic epithelial tumors and Good syndrome.
e20140 Background: Thymic epithelial tumors (TETs) are rare neoplasms often associated with paraneoplastic syndromes, which manifest as either autoimmune...
Examining age-specific trends in the incidence of anorectal cancer associated with human papillomavirus in the United States.
e15690 Background: The incidence of anorectal cancer has increased in the United States. We estimated the potential impact of HPV vaccination on anorectal...